Clinical Trial

CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the efficacy and safety of CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cell immunotherapy as first-line consolidation therapy in patients with follicular lymphoma.
Trial Details
NCT Number NCT07587840
Lead Sponsor Liping Dou
Conditions Lymphoma
Enrollment 20 participants
Start Date 2026-01-01
Primary Completion 2027-01-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-14